Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026
Company Deals

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Fineline Cube Mar 4, 2026
Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Fineline Cube Mar 5, 2026
Company Drug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

Fineline Cube Mar 5, 2026
Company Drug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

Fineline Cube Mar 5, 2026
Company Drug

GSK’s ViiV Healthcare Expands Dovato Indication to Include Adolescents with HIV-1 Infection

Fineline Cube Apr 9, 2024

GlaxoSmithKline’s (GSK; NYSE: GSK) ViiV Healthcare has received an indication extension from the US Food...

Company Drug

Johnson & Johnson’s Xarelto Demonstrates Reduced Bleeding Risk in Atrial Fibrillation Patients Post-PCI

Fineline Cube Apr 9, 2024

Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has announced positive results from a Phase...

Company Drug

Clover Bio’s SCB-1019 Vaccine Candidate Shows Promising Results in Phase I Trial

Fineline Cube Apr 9, 2024

Clover Biopharmaceuticals (HKG: 2197), a leading biotechnology company based in China, has announced robust preliminary...

Company Drug

Bristol Myers Squibb Reports Positive Long-Term Data for KarXT in Schizophrenia Trial

Fineline Cube Apr 9, 2024

Pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced preliminary long-term data from a...

Company Drug

Beijing Aosaikang Pharmaceuticals Achieves Clinical Milestone for c-MET Inhibitor ASKC202

Fineline Cube Apr 9, 2024

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced the presentation of promising data from...

Company Deals Drug Medical Device

Transcenta Holdings Ltd Collaborates with Agilent Technologies on Companion Diagnostic for Osemitamab

Fineline Cube Apr 9, 2024

China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced a strategic agreement with Agilent...

Company Drug

CStone Pharmaceuticals Submits New Drug Application for Gavreto in China, Eyes Local Manufacturing

Fineline Cube Apr 9, 2024

CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has submitted a market...

Company Deals

Medicxi-Led Investment Boosts D3 Bio’s Development of Best- in-Class Oncology Therapies

Fineline Cube Apr 9, 2024

UK life sciences investment firm Medicxi has taken the lead in a $62 million Series...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures IND Approvals for Two Drug Candidates from China’s NMPA

Fineline Cube Apr 9, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received Investigational New Drug (IND) approvals from...

Company Drug

Abbisko Therapeutics Achieves Milestone in Global Phase III Trial for Pimicotinib in Tendon Sheath Giant Cell Tumor

Fineline Cube Apr 9, 2024

Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the completion of subject...

Company Drug

Luye Pharma’s Subsidiary Boan Biotech Completes Phase III Trial for Eylea Biosimilar BA9101

Fineline Cube Apr 9, 2024

Shandong Boan Biotechnology Co., Ltd., a subsidiary of China-based Luye Pharma Group (HKG: 2186), has...

Company Medical Device

Adicon Launches GuardantOMNI Test to Advance Tumor Therapy Development in China

Fineline Cube Apr 8, 2024

Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory service provider, has announced the...

Company Deals

Merck Collaborates with Caris Life Sciences to Develop First-in-Class Antibody-Drug Conjugates

Fineline Cube Apr 8, 2024

German pharmaceutical giant Merck (ETR: MRK) has entered into a strategic collaboration with Caris Life...

Company Deals

Johnson & Johnson Acquires Shockwave Medical in a Landmark Deal to Expand Cardiovascular Portfolio

Fineline Cube Apr 8, 2024

Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has announced the acquisition of Shockwave Medical...

Policy / Regulatory

China’s CDE Issues Guidelines for Semaglutide Biosimilar Clinical Trials with Weight Management Focus

Fineline Cube Apr 8, 2024

The Center for Drug Evaluation (CDE) in China has released a new set of Guidelines...

Company Drug

AstraZeneca’s Imfinzi Achieves Positive Results in Late-Stage Trial for Small Cell Lung Cancer

Fineline Cube Apr 8, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that a late-stage trial for its...

Company Drug

Novartis’s Leqvio Showcases Real-World Efficacy in Managing Cholesterol in ASCVD Patients

Fineline Cube Apr 8, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented compelling real-world data for its innovative small...

Policy / Regulatory R&D

Beijing Unveils Comprehensive Measures to Boost Innovative Medicine Development

Fineline Cube Apr 8, 2024

The Beijing Municipal Medical Insurance Bureau, in conjunction with eight other bureaus, has announced a...

Policy / Regulatory

Guangzhou and Zhuhai Unveil Measures to Stimulate Biopharmaceutical Industry Growth

Fineline Cube Apr 8, 2024

In a bid to bolster the biopharmaceutical and health industries, the cities of Guangzhou and...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Secures FDA Approval for HER2-Positive Solid Tumors

Fineline Cube Apr 8, 2024

Partners AstraZeneca (AZ; NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have been granted an additional...

Posts pagination

1 … 342 343 344 … 631

Recent updates

  • HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors
  • AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12
  • China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion
  • AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics
  • Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

Company Drug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.